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ABSTRACT 
Background: Ultra-micronized palmitoylethanolamide (um-PEA) represents an attractive 
option for chronic pain control in complex older patients at higher risk of adverse effects 
with traditional analgesics.  
Objective: To determine the effectiveness of um-PEA versus placebo on chronic pain 
intensity and function in individual geriatric patients. 
Design Randomized blinded N-of-1 trials with two 3-week um-PEA versus placebo 
comparisons, separated by 2-week washout periods. 
Participants: Outpatients aged ≥65 with chronic non-cancer non-ischemic pain in the 
back, joints or limbs. 
Intervention: Um-PEA 600 mg or placebo twice daily. 
Measurements: Pain intensity using an 11-point visual numeric scale; functional 
impairment using a Back Pain Functional Scale; impact of each N-of-1 trial on the 
clinician’s intention to treat and confidence. 
Results: 10 of 11 eligible patients consented over 7 months (all female, mean age 83.2 
years [SD, 4.6]). Three patients interrupted the trial: 1 had diarrhea (under placebo), 1 
for low adherence, and 1 for intercurrent pneumonia. A small statistically significant 
effect in favor of um-PEA was seen at the mixed method analyses in 2 patients (effect 
size equal to 8% of the baseline pain). A statistically significant impact on function was 
found in 1 patient. After the trial: um-PEA was prescribed to 4 patients; in 2 patients the 
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clinician changed her pre-trial intention to treat; the clinician confidence in the 
treatment plan either increased (5) or remained the same (2). 
Conclusions: Our experience confirmed that N-of-1 trials may help make personalized 
evidence-based decisions in complex older patients, with special feasibility 
considerations.  
ClinicalTrials.gov NCT02699281. 
Funding: none. 
Key points 
 We performed randomized controlled trials on single outpatients (N-of-1 trials) 
referring to our geriatric clinic to assess the effectiveness of 
palmitoylethanolamide (PEA) on chronic pain in each individual. 
 This was a pilot for a Geriatric N-of-1 Service that would help physicians to 
conduct N-of-1 trials in clinical practice as an instrument for evidence-based and 
personalized therapeutic decisions in geriatric patients. 
 We confirmed that this approach is attractive also in this population, but some 
specific feasibility aspects need to be taken into account. 
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1. INTRODUCTION 
The reported prevalence of chronic or persistent pain among the elderly is as high as 
80%;1 osteoarthritic back pain is the most frequent noncancer cause.2  Chronic pain and 
its inadequate treatment have an important impact on patient function, autonomy, 
quality of life, and healthcare resource use.3 Age-related changes in the somatosensory 
system and in drug pharmacokinetics, together with a higher chance of drug-drug and 
drug-disease interactions, influence the efficacy and safety of the available analgesic 
and pain-modulating drugs.4-9 
In particular, a growing body of evidence suggests that immune cells like microglia and 
mast cells play a substantial role in the induction, amplification, and maintenance of 
chronic pain especially with aging.9-12 After an injury or in the presence of an 
inflammatory stimulus, immune cells, which are located in proximity to sensory nerve 
endings and vasculature, release mediators stimulating nociceptors. Physiological 
activation of microglia generally leads to resolution of neuroinflammation and 
restoration of tissue homeostasis. With aging, both microglia and mast cells increase 
their reactivity to stimuli, with a consequent more robust and long-lasting production of 
pro-inflammatory cytokines. These findings support the hypothesis that non-neuronal 
cells might be important therapeutic targets for the treatment of chronic pain, 
especially in older persons. Palmitoylethanolamide (PEA) is an endogenous N-acyl-
ethanolamina involved in the modulation of neuroinflammation processes.13-15 In 
murine models of chronic inflammation and chronic or neuropathic pain, PEA has been 
found to reduce the recruitment and activation of mast cells, the production of pro-
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inflammatory mediators, and endoneural edema, thus reducing both pain and 
inflammation while preserving peripheral nerve morphology.13,14 Several products 
containing micronized or ultra-micronized PEA (um-PEA) are authorized in Europe as 
“Food for Special Medical Purposes” (European Commission Directive 1999/21/EC). PEA-
based products might represent a safe choice for pain control or modulation in older 
people. In a systematic review including patient-level data from randomized and non-
randomized trials, PEA was found to be effective in reducing chronic pain, 
independently of sex, age, and type of pain, even if with a smaller effect in people over 
age 65.16 No serious product-related adverse events were reported.16 
Response to many drugs used to treat pain varies across individuals,16,17 and this is likely 
true for um-PEA.  This likely variability, and the necessity for purchase out-of-pocket, 
represented the rationale to use N-of-1 trials (within-patient, randomized, multi-period, 
crossover, blinded studies) to help decide, case by case, whether to prescribe PEA in our 
geriatric patients.  Clinicians have previously used N-of-1 designs to optimize the 
pharmacological management of chronic conditions including pain, using randomization 
and blinding as strategies to overcome bias (e.g. natural history of the disease, placebo 
effect, clinician and patient expectations) that threaten the trustworthiness of the “treat 
and see” trials routinely used in practice.18-20 In this report, we present a series of N-of-
trials addressing PEA for chronic pain in older patients, conducted in the context of our 
Geriatric N-of-1 Service, i.e. an experimental project we implemented taking inspiration 
from previous pioneering experiences21,22 but in the specific setting of the geriatric 
medicine.   
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2. METHODS  
A previous publication presents the full study protocol with detailed rationale and 
methods.23 This study was part of the Geriatric N-of-1 Service project, approved by the 
ethical committee of the Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, 
Milan, Italy. The primary objective of the study was to apply the N-of-1 trial approach to 
test the effectiveness of um-PEA 600 mg (Normast®) twice a day for chronic pain in 
individual patients referred to the geriatric outpatient clinic of our University Hospital. 
As a secondary methodological objective, the study included a meta-analysis of the N-
of-1 trials performed comparing the frequentist and the Bayesian statistical 
approach.24,25 The present report focuses on the primary objective, and follows the 
guidelines of the CONSORT extension for reporting N-of-1 trials (CENT) 2015 
Statement.26   
2.1 Design Overview, Randomization, and Blindness 
Figure 1 presents the trials’ structure. The expected total length of each trial was 18 
weeks, comprising 2 um-PEA and placebo treatment pairs assigned in a random order 
according to a pairwise randomization scheme.  Patients took one tablet containing 
either Normast® 600 mg or placebo orally twice daily during the treatment periods, with 
no use of study drug during the washout period.  Patients used other pain medication 
on an as needed basis.  The product information sheet for Normast® 600 mg suggests 
“1-2 tabs a day for 20-30 days”, but onset times longer than 1 week might be expected 
“especially for chronic pain syndromes”;27 a possible carryover effect is also possible. 
Thus, the uncertain pharmacological characteristics of the product, and the desirability 
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of avoiding too long trials, dictated two pairs of treatment periods of 3 weeks each with 
2-week washout intervals.  
Epitech Group SpA provided the active and placebo drugs, with no other involvement in 
the study. The study drugs were stored at the hospital pharmacy. For each trial, a 
hospital pharmacist generated the random sequence of treatments using the web site 
www.randomizer.org, recorded the randomization codes, and provided the study drug 
at the beginning of each study period, thus allowing the patients, caregivers, treating 
physicians, and statistician to remain blinded to the sequence of active and placebo 
treatment.  
When the trial was concluded, the clinical investigators and statisticians interpreted the 
results, and discussed results with the treating physician and, when feasible, with the 
patient/caregiver at first maintaining the data blinded. Only secondarily the code was 
broken and the definitive decision upon whether to continue um-PEA was taken.  
2.2 Participants 
Outpatients 65 years of age or older with a complaint of non-cancer chronic pain in the 
back, joints or limbs for at least 6 months were invited to participate in the study if the 
treating physician considered um-PEA as a possible treatment option for the patient but 
was uncertain about its advisability.  We excluded patients with subacute or chronic 
limb ischemia and those who had recently commenced a new pharmacological or non-
pharmacological treatment for pain.  
2.3 Outcomes 
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In each N-of-1 trial patients rated the intensity of their pain daily using an 11-point 
(from 0 to 10) visual numeric scale28 in which labels and pictures (modified from the 
Faces Pain Scale29) were included with the numeric horizontal line (eFigure 1). In the 
same daily sheet, the patient was asked to report also every time he/she needed to take 
analgesic medications, specifying the name and dosage. The impact of pain on daily 
activities was evaluated at end of each week, using a short questionnaire modified from 
the Back Pain Functional Scale (BPFS).30,31 The BPFS consists of 12 items investigating the 
performance at work, hobbies, home activities, bending or stooping, dressing shoes or 
socks, lifting, sleeping, standing, walking, climbing stairs, sitting and driving.  We 
modified the BPFS by allowing patients to omit items that did not apply when the 
patient was not used to perform that activity, regardless of pain (e.g. if she was not used 
to driving or to have specific hobbies); while items that could potentially apply but were 
“impossible” to the patient because of the pain, were kept in. Each item was rated using 
a Likert 5-point scale (1 = no difficulty to perform activity; 2 = little difficulty; 3 = medium 
difficulty; 4 = great difficulty; 5 = impossibility to perform the activity. The statistical 
analysis was based on the mean score of the completed items.  
The physicians reported their intention whether or not to treat the patient with um-PEA 
before and after the trial, answering the question “If the patient was not going to 
participate in the trial, would you treat him/her with um-PEA?”, before the trial; and the 
question “Now the trial has terminated and you know the results, would you continue 
treating the patient with um-PEA?”, after the trial. Both before and after, the physicians 
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answered also the question “How comfortable do you feel now about your treatment 
plan?” using a 7 point scale.22 
2.4 Statistical methods 
In accordance with the study primary objective, each trial was analyzed separately. For 
each patient, the effect on daily pain intensity was represented graphically as the mean 
scores over each week and over each period. A similar graphical presentation was used 
for the weekly scores of function impairment.  The effect of the active treatment versus 
placebo in each patient was first statistically evaluated through a paired t-test of the 
period mean scores within treatment pairs, as previously done in similar studies.22 
Secondarily, to use a more statistically powerful approach, we analyzed the patient’s 
daily data on pain intensity, or the weekly data on function impairment, without 
aggregating them into period mean scores, in linear mixed effect models, with the daily 
data on pain intensity, or the weekly data on function impairment, as dependent 
variable, and the treatment (active versus placebo) as independent variable. We used 
mixed effect models, at first, to include the treatment pair (first or second pair) as 
random intercept, in order to account for a possible correlation between data within 
pair, to be consistent with the trial design, and allow comparison with the paired-t test 
analyses. However, using the likelihood ratio test, for each trial, we compared the mixed 
effect model to a linear regression model to verify the pairwise structure of the data. 
The main analyses were performed assuming that the washout periods were sufficient 
to overcome the possible carryover effect of PEA. As sensitivity analyses, the models 
were repeated after excluding the measures made during the first week of each period 
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in order to account for a slow onset time and/or a residual carryover effect.32 When the 
graphical representation suggested a clear trend over time (e.g. a pain or function 
ratings consistently increased or decreased over the course of the trial regardless of the 
treatment, with a visual difference between the first two and the last two periods of 
treatment), we statistically verified this by including in the model an interaction term 
between treatment and pair (e.g. first pair of treatment versus second pair of 
treatment), and discussed a possible reason with the patient.   
Missing data were expected. No imputation method was planned. If more than 3 
measures of the daily pain intensity in the same week were missing for at least one 
week, the period mean score was computed weighting each week mean score according 
to the inverse-variance method.33  
Given the heterogeneity in the way they were reported, data on the daily use of pain 
medications, on a demand base, were not formally analyzed. They were summarized for 
each week as the weekly mean number of times in a day in which the patient assumed a 
medication (any type, any dosage), and included in the graphical representation that 
was shown to the patient and the treating physician as an additional element for the 
discussion (eFigure2).  
Each trial was eventually classified according to its completeness and the statistically 
significance of its results (threshold p value ≤ 0.1).   
 
3. RESULTS 
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In the period between September 2015 and March 2016, we suggested participation to 
11 patients referred to the outpatient geriatric clinic and complaining for chronic pain 
who met the eligibility criteria. The study flow diagram is reported in eFigure 3. Table 1 
presents the baseline characteristics of the 10 patients who initially consented to 
participate and started the trial. All patients were female, with a mean age of 83.2 years 
(SD 4.6 years). Only 3 patients were on chronic analgesic therapy at the time of 
enrolment (patient 2, 5, 10), with a history of multiple pharmacological failures, and 
different pain etiologies additional to osteoarthritis. All patients used to take painkillers 
on demand.  
Table 2 synthesizes the methods and completeness of individual N-of-1 trial. Three 
patients did not complete the trial. Patient 1 interrupted the trial because of diarrhea in 
the first 4 days during which she was taking placebo. Patient 4 withdrew before the last 
period, but since her adherence was suspected to be low since the beginning because of 
behavioral issues (eventually found to be related to an initial dementia), we did not 
further consider her data. In one case (patient 10) the trial was interrupted due to 
intercurrent illness. Among the 7 patients in which the trial was conducted through the 
last period, outcome questionnaires were returned with no missing data in one case 
(patient 5); in the case of patient 3, the questionnaires for periods 3 and 4 were lost and 
never returned; in all the other cases, questionnaires were returned with few missing 
data.  
Table 3 presents results on pain intensity of individual trials according to different 
statistical approaches. Figure 2 shows the corresponding graphical results as presented 
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to the treating physicians, patients, and caregivers. eTable 1 in the supplement presents 
individual results of functional impairment. eTable 2 presents a more detailed synthesis 
of outcome data of the N-of-1 trial of patient 5. Table 3 shows the impact on physician’s 
therapeutic choice and confidence, and follow-up data.  
Overall, both daily pain intensity scores (table3, figure 2) and weekly function 
impairment scores (eTable 1) generally showed small variations over the trial. None of 
the studies showed a statistically significant difference in pain intensity between um-
PEA and placebo using the paired-t test of mean period pain intensities (table 3). A 
statistically significant effect was seen at the mixed method analyses either in favor of 
um-PEA for patients 2 and 9 (with an effect size that corresponded in both case to about 
8% of the baseline pain), or in favor of placebo for patients 3 and 5. The sensitivity 
analyses accounting for a possible carryover effect and slow onset not sufficiently 
overcome by the scheduled washout, supported a probable favorable effect of um-PEA 
in patients 2 and 9, and suggested a possible favorable effect in patient 5 and 6. In 
patient 5, the graphical representation (figure 2) suggested a slow onset, the need for 
drug titration and a delayed carryover effect. A pair effect was statistically significant in 
patients 8 and 9. In the former case, it was mainly attributed to the onset of 
stomachache in the second part of the trial; in the latter, a clear reason for a sharp pain 
improvement in the second part of the trial could not be found. The reported daily need 
for on-demand pain medication was consistent with the intensity of pain. A statistically 
significant favorable effect on function impairment was seen only in patient 7 (eTable 
2), who on average reported a relatively low impact on functional impairment during 
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the trial according to the questionnaire, and eventually placed a low value on the effect 
on function against the lack of effect on pain intensity. 
After the discussion of the results and experience of the trial with the treating 
physicians, patients, and caregivers, 4 patients continued with um-PEA (table 3). In all 4, 
the physician’s intention before the trial was to treat with um-PEA; in 2 patients the 
level of confidence in the decision increased after the trial; in 2 cases it remained the 
same (Table 3). Three of these 4 patients were still using um-PEA at the first clinical 
follow-up (table 3). Three patients were not prescribed um-PEA; in 1 case this coincided 
with the physician’s pre-trial intention, while in 2 cases the physician’s intention before 
the trial was to treat the patient. In all 3 cases, the confidence in the decision increased 
after the trial. 
5. DISCUSSION 
We report the results of a series of N-of-1 trials to test the efficacy of um-PEA in 
reducing chronic non-cancer pain and its impact on function performed in older 
outpatients referred to the geriatric clinic of our University hospital in Milan. We found 
a statistically significant favorable impact on either pain intensity or function 
impairment in 3 of 7 patients that completed the trial; in the other 4 completed trials, 
the results did not reach a statistical significance or were in favor of placebo. After the 
trial, um-PEA was prescribed to 4 patients. In 2 patients, the physician changed her pre-
trial intention to treat the patient with um-PEA based on trial results. In 5 patients, the 
clinician expressed greater confidence in the decision after the trial; in 2 patients the 
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pre-trial level of confidence (i.e. “Quite comfortable, likely that the treatment plan is 
best for the patient”) was unaffected by the trial.  
Our study has several strengths. It was the first time a series of N-of-1 trials was 
implemented with the aim of optimizing pain medication, through an empirical, 
objective and personalized approach, specifically in geriatric patients. These N-of-1 trials 
represent a pilot of a wider project aiming to create a Geriatric N-of-1 Service, based on 
the rationale that older complex patients are underrepresented in the current 
paradigms of the evidence based medicine,34,35 extremely heterogeneous, and are often 
exposed to therapeutic failures and adverse events.  Such patients therefore stand to 
benefit from use of a method that would establish or refute benefit with greater 
certainty than conventional multiple “try and see” trials,19 and from an approach that 
would put patient characteristics, needs and preferences at the center.36,37 The specific 
context of chronic pain management, often associated with long term use of multiple 
medications and abuse of nutraceuticals despite unclear benefit,38,39 and the specific 
case of um-PEA, with the need for the patient to pay cover the product cost, 
contributed to our motivation. Our experience has commonalities with previous 
experiences with N-of-1 trials not specifically conducted in a geriatric setting.22,23,40 First, 
the approach helped to strengthen the confidence in the therapeutic decisions, whether 
the decision was a confirmation of a pre-trial intention or not, and, often, independently 
of the statistical significance of the results. Second, the graphical representation of the 
results, more than statistics, played a role in the decision making process involving 
patients, caregivers and treating physicians, as did in similar experiences.22 The lack of 
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power of statistical tests, and the potentially compelling impact of visual presentation of 
results, has made practitioners of single-subject studies question the necessity of 
statistical tests.41 The analysis of N-of-1 trials based on a paired-t test is consistent with 
treatment periods being the unit of randomization, and with the pairwise structure, but 
it is known to have a limited statistical power.42 Visual presentation of results mitigates 
this limitation in practice. However, we were aware that patients, caregivers and, above 
all, physicians, even when able to appreciate the visual presentation, would sometimes 
rely on us for advice on the trial results from a more analytical perspective. Thus, we 
decided to use also mixed methods, which, still accounting for the trial structure, would 
allow using all the daily (or weekly) outcome measurements, yielding a greater power. 
Therefore, the difference in the statistical significance of the results between the two 
tests, for the same trial, in some of the patients, was someway expected.   
We also learned lessons regarding the feasibility of this approach with the oldest 
patients. Compliance and reliability of the patients represented the main anticipated 
threats to the trials, which we tried to reduce through enrolling patients whom we had 
already evaluated based on a comprehensive geriatric assessment, who appeared to be 
keen to undertake such a type of trial that would help them with their pain, and who, in 
a screening visit, when instructed on how to complete the questionnaire, demonstrated 
their ability to do so. In fact, in only one of 10 patients did the trial fail because of 
patient’s noncompliance, which corresponds to a similar noncompliance rate (10%) as 
what a previous report of a 3-year experience with N-of-1 trials and a case mix that 
included also younger patients.22  
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In terms of adherence to the drug protocol, in their proof-of-concept series of N-of-1 
trials on statin-related myalgia in patients with a relatively lower mean age than ours 
(66 years, female in 7 of 8 cases),40 Joy and colleagues reported a 92 to 100% adherence 
based on pill counts. We decided not to formally assess adherence in this way because it 
would not definitely prove a correct daily dose regimen. Similarly, previous reports of N-
of-1 trials have also described instances in which patients forgot to complete the 
questionnaires for a certain period, or lost the questionnaires, or did not adhere 
temporarily to the trial design.40 In some cases, we suspected, on the basis of clinical 
contact and the way they patients completed the questionnaires, that their reliability 
was lower than expected from their MMSE score at the screening visit.  In some 
patients, especially in those with no etiologies other than osteoarthritis, we suspected 
that the patient’s inurement to pain, together with reduced discernment abilities, 
explained average moderate outcome scores with small variation. Indeed, the fact that 
most of these patients, despite complaining about pain, were not on chronic analgesic 
therapy, was already a clue for their tendency to resist pain. In particular, it has been 
our own experience that older patients tend to underestimate the medical importance 
of pain, compared with other medical conditions they are affected by, which might be a 
fact related to age but also to our own cultural background, therefore not necessarily 
generalizable. However, we cannot exclude that our patients were not on any chronic 
analgesics because of (patient’s or physician’s) low confidence in their efficacy and/or 
safety, or because pain had been previously underestimated or overlooked by other 
physicians. Finally, we encountered social barriers that we tried to address. For instance, 
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in one patient, because she lived alone and had mobility limitations, we delivered the 
study drugs and questionnaires to her home. In another patient, because there were no 
close relatives, we engaged a patient’s friend who, eventually, withdrew from her 
caregiving role.  
Lastly, we experienced some feasibility issues previously described as obstacles to the 
adoption of N-of-1 trials in practice: difficulties in educating, involving and keeping 
engaged the medical staff.43 Conversely, we easily succeeded in involving the hospital 
pharmacy to store and deliver the study drugs, generate the randomization schemes, 
and ensure blindness.  
5.1 Limitations 
In designing the study, we needed to compromise to take into account the expected 
pharmacological characteristics of um-PEA. Hence, we conducted trials of about 4 
months each, with the awareness that we were at the limit beyond which important 
criteria for an N-of-1 trial to succeed, including patient compliance and clinical stability, 
are jeopardized.41,44 Second, we designed the study based on evidence about the 
product pharmacokinetics and pharmacodynamics that are not definitive, with a 
possible inter-individual variability that could not be anticipated. Our trials could be an 
opportunity to explore the product characteristics further; yet, the trial structure might 
have been not completely appropriate to study the product efficacy in every case. Third, 
even though chosen after a careful review of the relevant literature, we could not 
exclude that the instruments we used were not fully appropriate; in particular, we could 
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not exclude that the instruments’ limitations contributed to the small variations that the 
patients overall reported.  
5.2 Conclusions 
In conclusion, our series of N-of-1 trials on um-PEA to reduce the intensity and the 
impact on function on chronic non-cancer pain in a geriatric outpatient setting 
represented the opportunity to test the feasibility of this approach to make 
personalized evidence based decisions in complex older patients. We can confirm that 
the approach remains attractive in this population, but requires special considerations 
beyond those suggested in the users’ guide proposed by the pioneers of the 
method.41,44 Our experience demonstrates that the final objective of creating “a real 
clinical learning community”45 was achieved, and that the approach facilitates older 
patients’ desire to participate in decision making and research.46 
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Figures’ captions 
 
Figure 1. N-of-1 trial design  
 
Figure 2. Effect on pain intensity based on treatment period in individual N-of-1 trials 
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Table 1. Baseline characteristics  
Characteristics  All patients (n=10) 
Mean age (SD, range), y 83.2 (4.6, 74-89) 
Female, n (%) 10 (100) 
Living condition, n (%) 
 Alone 
 With partner 
 With other relatives 
 With a formal caregiver 
 Nursing home resident 
 
4 (40) 
5 (50) 
0 (0) 
1 (10) 
0 (0) 
Mean, median ADL (SD, range) 4.8, 5 (1.2, 3-6) 
Mean, median IADL (SD, range) 6.1, 7.5 (2.4, 2-8) 
Mean, median MMSE (SD, range) 28.4, 29 (1.6, 26-30) 
Mean, median Charlson Comorbidity Index (SD, 
range) 
1.5, 2 (1.3, 0-3) 
Mean, median number of drugs (SD, range) 7.2, 7.5 (3.4, 1-13) 
Mean eGFR (SD) 56.5 (17.9) 
Pain: location, n (%) 
 Back (alone) 
 Back and joints 
 Back and limbs 
 Joints (alone) 
 Joints and limbs 
 Limbs (alone) 
 Back, joints and limbs 
  
2 (20) 
4 (40) 
2 (20) 
0 (0) 
0 (0) 
1 (10) 
1 (10) 
Pain: etiology, n (%)a 
Degenerative (osteoarthritis /osteoarthrosis 
/spondylosis /radiculopathy) 
 Diabetic neuropathy 
 Post-herpetic neuralgia 
 Restless leg syndrome 
 Post-trauma 
  
10 (100) 
 
1 (10) 
1 (10) 
1 (10) 
1 (10) 
Patients on chronic analgesic therapy, n (%) 3 (30)b 
Baseline pain assessment  
Mean, median pain intensity scorec (SD, range) 
Mean, median impact on function scorec (SD) 
 
5.4, 5.7 (1.3, 3-7) 
2.8, 2.4 (0.8, 1.9-4.2) 
Abbreviations: SD, standard deviation; ADL, basic Activity of Daily Living (Katz scale); IADL, Instrumental 
Activity of Daily Living (Lawton scale); MMSE, Mini Mental State Examination; eGFR, estimated glomerular 
filtration rate (Cockcroft-Gault formula) 
a The table lists non exclusive etiologies. All patients had a degenerative cause of persistent pain; some 
have also additional causes.  
b At the time of the enrollment, 1 patient was taking gabapentin and clonazepam, 1 only gabapentin, and 
1 duloxetine 
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c The baseline pain intensity and function impairment for each patient has been defined as the mean 
between the value given the day in which the patient consented to the trial and the value given the first 
day of the trial, to take into account the daily fluctuations of chronic pain. Indeed, these two values were 
substantially different in some patients.  
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Table 2. Methods and completeness of individual N-of-1 trials  
 
ID 
Randomization 
sequence 
Person in charge of 
filling outcome 
questionnaires 
Trial 
completeness 
Completed 
periodsa 
Reasons for 
incompleteness 
Notes 
1  PA - PA Patient Incomplete None 
Acute incoercible 
diarrhea after 4 days 
from the beginning of 
the trial without clear 
alternative explanations 
The sequence was open and the patient was 
showed she was taking the placebo drug. 
She recovered from diarrhea in few days; 
the diarrhea was judged to be of unclear 
origin, and the patient was offered to restart 
the trial. The patient refused.  
2  AP - PA Patient Complete 1, 2, 3, 4, 5, 6, 7 - - 
3  AP - PA 
Patient with 
daughter’s help 
Complete 1, 2, 3, 4, 5, 6, 7 - 
The patient completed each trial’s period 
but did not return the questionnaires for 
period 3 and 4 
4  AP - PA 
Patient with a 
friend’s help 
Incomplete 1, 2, 3, 4, 5, 6 
Withdrawal, low 
compliance 
The patient was suspected to have low 
compliance to the trial protocol; hence, 
even data for completed periods were 
judged unreliable and not analyzed 
5  AP - AP 
Patient with 
husband’s help 
Complete 1, 2, 3, 4, 5, 6, 7 - - 
6  PA - AP Patient Complete 1, 2, 3, 4, 5, 6, 7 - - 
7  PA - AP Patient Complete 1, 2, 3, 4, 5, 6, 7 - - 
8  PA - AP 
Patient with formal 
caregiver’s help 
Complete 1, 2, 3, 4, 5, 6, 7 - 
In the second part of the trial the patient 
complained for stomachache for which she 
started assuming antacid and antispasmodic 
drugs (Mg hydroxide and hyoscine 
butylbromide) almost daily. Also, patient 
cognition deteriorated during the trial. The 
trial was however continued. 
9  AP - PA Patient with Complete 1, 2, 3, 4, 5, 6, 7 - The patient discontinued the trial at the end 
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daughter’s help of period 2 (i.e. first washout) for 16 days, 
for unclear reasons; then the trial was 
restarted from period 3 and completed. 
10  AP - AP Patient Incomplete 1, 2 
The patient was 
hospitalized for 
pneumonia 
 
Abbreviations: ID, patient number; A, active drug (um-PEA); P, placebo 
aPeriods were considered completed when the patient followed the trial design and took the active drug or placebo or nothing, according to the schedule, 
regardless of the presence and number of missing outcome data. See Figure 1 for each trial structure and period numbering.   
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Table 3. Results of completed N-of-1 trials: effect on pain intensity, physician’s 
treating plan and confidence, and follow-up data 
ID 
Pain Intensity 
Physician’s 
treating plan and 
confidence  
First clinical follow-up 
Mea
n 
dail
y 
scor
e 
(SD) 
duri
ng 
the 
trial 
Wee
ks 
with 
at 
leas
t 3 
days 
with 
miss
ing 
data
, n 
Mean difference (95% CI)a, p 
value Intentio
n to 
treat 
with 
um-PEA 
BEFORE 
the trial 
(confide
nced) 
Decisio
n to 
treat 
with 
um-PEA 
AFTER 
the trial 
(confide
nced) 
Patient 
treate
d with 
um-
PEA 
(mont
hs 
since 
N-of-1 
trial 
comple
tion) 
Clinical notes 
Paired 
t test 
Mixed 
effect 
modelb 
Mixed 
effect 
model, 
sensitiv
ity 
analysi
sc 
2 
6.6 
(0.5) 
2 
-0.50 
(-0.56, 
0.46)e 
p=0.44
3 
-0.40 
(-0.66, -
0.14) 
p=0.00
3 
-0.67 
(-0.87, -
0.46) 
p<0.00
1 
To treat 
(5) 
To treat 
(5) 
Yes (3) 
After a month 
of open 
therapy, the 
patient opted to 
continue with 
um-PEA even if 
“it had only a 
small effect on 
her pain” 
3 
5.6 
(1.1) 
5f 
0.53 
(-1.12, 
2.19)g 
p=0.30
0 
0.90 
(0.36, 
1.44) 
p=0.00
1 
1.21 
(0.49, 
1.94) 
p=0.00
2 
Not to 
treat (3) 
Not to 
treat (7) 
No (12) 
The patient had 
started 
pregabalin some 
months before 
with partial pain 
relief  
5 
5.2 
(1.6) 
0 
1.00 
(-12.31, 
14.31) 
p=0.51
5 
1.00 
(0.33, 
1.67) 
p=0.00
3 
0.32 
(-0.49, 
1.13) 
p=0.43
6 
To treat 
(5) 
To treat 
(5) 
No (6) 
After 10 days of 
open therapy 
with um-PEA, 
the patient 
presented fluid 
retention and 
withdrew the 
drug (with no 
symptom 
improvement). 
She never 
resumed um-
PEA afterwards.  
6 
5.2 
(0.8) 
0 
-0.05 
(-5.77, 
5.67) 
p=0.93
0 
0.01 
(-0.31, 
0.32) 
p=0.96
9 
-0.33 
(-0.66, 
0.01) 
p=0.05
6 
To treat 
(5) 
To treat 
(6) 
Yes (4) 
The patient 
referred a mild 
effect on pain 
after the first 
month of open 
therapy and was 
prescribed with 
continuing um-
PEA every other 
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month. 
7 
4.3 
(1.3) 
3h 
-0.25 
(-5.97, 
5.47) 
p=0.67
7 
-0.29 
(-0.83, 
0.26) 
p=0.30
6 
0.25 
(-0.31, 
0.81) 
p=0.30
6 
To treat 
(4) 
Not to 
treat (6) 
No (10) 
The patient 
never showed 
up at the 
scheduled 
follow-up visits 
at the geriatric 
clinic in the 8 
months after 
the completion 
of the trial. She 
was contacted 
by phone. 
8 
4.9 
(2.1) 
1 
0.55 
(-20.41, 
21.51) 
p=0.79
5 
0.53 
(-0.35, 
1.42) 
p=0.23
8 
0.91 
(-0.22, 
2.04) 
p=0.11
4 
To treat 
(4) 
Not to 
treat (6) 
No (9) 
The patient 
referred a 
spontaneous 
attenuation of 
her back pain. 
The 
stomachache 
she had 
referred during 
the trial 
occurred 
intermittently 
also later. 
9 
4.1 
(1.4) 
0 
-0.65 
(-20.34, 
19.04) 
p=0.74
7 
-0.67 
(-1.21, -
0.13) 
p=0.01
5 
-0.86 
(-1.51, -
0.20) 
p=0.01
0 
To treat 
(4) 
To treat 
(6) 
Yes (5) 
The patient 
referred a 
satisfactory 
control of her 
pain with um-
PEA and on-
demand 
acetaminophen. 
Abbreviations: ID, patient number; SD, standard deviation; CI, confidence interval; A, active drug (um-
PEA); P, placebo; um-PEA, ultra-micronized palmitoylethanolamide 
a Calculated as active-minus-placebo difference (i.e. a positive mean indicates greater pain while 
receiving um-PEA versus placebo, whereas a negative mean indicates greater pain intensity while 
receiving placebo) 
b Linear mixed effect model with the daily pain intensity as dependent variable, and pair included as 
random effect (random intercept). 
c Calculated using the same linear mixed effect model as in note b but after excluding the outcome 
assessments made in the first week of each treatment period to reduce the effect of possible drug’s 
slow onset and/or carryover effect.  
d 1=Extremely uncomfortable, uncertain about the treatment plan and, if wrong, the patient may 
suffer. 2=Moderately uncomfortable, feeling that the treatment plan may not be the best for the 
patient. 3=Mildly uncomfortable, some uncertainty whether the treatment plan is best for the 
patient. 4=Not totally comfortable, but treatment plan is very likely to be as good as alternatives. 
5=Quite comfortable, likely that the treatment plan is best for the patient. 6=Almost totally 
comfortable, very likely it's the right thing for the patient. 7=Totally comfortable, certain it's the right 
thing for the patient.  
e Pain intensity data were missing for the entire week for 2 weeks of the same period (period 5, while 
the patient was taking placebo). The results shown in the table were obtained computing the mean 
period score ignoring the missing data. Secondarily, the mean difference was also computed 
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weighting each period mean score based on data missingness using the inverse-variance method. 
Even if only 7 out of 21 assessments were available, they all corresponded to a score of 7. Thus the 
analysis based on the inverse-variance method (taking into account the number of assessments but 
also the data variance) provided a larger statistically significant effect size favoring the active drug 
(with high data heterogeneity according to the I-squared test). 
fData missing for every week of period 3 and every week of period 4 (washout) because outcome 
assessments were lost and not returned 
gPaired t test on period means could not be performed because data for the entire period 3 were 
missing. For this patient, the table shown the results for the paired t test on week means of the 
second pair of treatment  
hAll weeks with missing data were in washout periods 
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